Multiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis
Authors:
- Juliana MansurJMJuliana Mansur
- Domingo Chang-DávilaDCDomingo Chang-Dávila
- Marcela Giraldes SimõesMSMarcela Giraldes Simões
- Marina Pontello CristelliMCMarina Pontello Cristelli
- Laila Almeida VianaLVLaila Almeida Viana
- Alexandra Nicolau FerreiraAFAlexandra Nicolau Ferreira
- Marisa Petrucelli DoherMDMarisa Petrucelli Doher
- José Medina-PestanaJMJosé Medina-Pestana
- Gianna Mastroianni KirsztajnGKGianna Mastroianni Kirsztajn
- Helio Tedesco-SilvaHTHelio Tedesco-Silva
Open Access
- 28 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1651
Abstract
Background. There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results. Methods. This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients. Results. Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis. Conclusions. In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events. ExportKeywords
This publication has 16 references indexed in Scilit:
- Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide studyAmerican Journal of Transplantation, 2021
- Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical PerspectiveNephron, 2020
- Clinical features and outcomes of kidney transplant recipients with focal segmental glomerulosclerosis recurrenceNephrology, 2019
- Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS studyBMC Nephrology, 2018
- A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantationScience Translational Medicine, 2014
- Focal segmental glomerulosclerosis after renal transplantationClinical Transplantation, 2011
- Recurrence of focal segmental glomerulosclerosis in renal allograft: An in-depth reviewPediatric Transplantation, 2010
- Intensive and Prolonged Treatment of Focal and Segmental Glomerulosclerosis Recurrence in Adult Kidney Transplant Recipients: A Pilot StudyAmerican Journal of Transplantation, 2009
- Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipientsNephrology Dialysis Transplantation, 2005
- Circulating Factor Associated with Increased Glomerular Permeability to Albumin in Recurrent Focal Segmental GlomerulosclerosisNew England Journal of Medicine, 1996